Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sarah Axelrath"'
Publikováno v:
Harm Reduction Journal, Vol 21, Iss 1, Pp 1-4 (2024)
Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine
Externí odkaz:
https://doaj.org/article/3f836810155447e9927d8ffcfdf50841
Autor:
Sarah Axelrath
Publikováno v:
JAMA network open. 5(8)